Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Functional analysis of ANGPTL8 in clear cell renal cell carcinoma

ABSTRACT: Functional analysis of ANGPTL8 in clear cell renal cell carcinoma

PROVIDER: PRJNA840845 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19331606_1.fastq.gz	Fastqsanger.gz
	SRR19331606_2.fastq.gz	Fastqsanger.gz
	SRR19331607_1.fastq.gz	Fastqsanger.gz
	SRR19331607_2.fastq.gz	Fastqsanger.gz
	SRR19331608_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Functional analysis of ANGPTL8 in clear cell renal cell carcinoma

Project description:To investigate the function of ANGPTL8 in clear cell renal cell carcinoma, Caki-1 cells overexpressing ANGPTL8 and ANGPTL8 knockout were established.

2022-05-25 | GSE203429 | GEO

CTSP Kidney Renal Clear Cell Carcinoma E2805T6

Project description:CTSP Kidney Renal Clear Cell Carcinoma E2805T6

| PRJNA562745 | ENA

ARID2 promotes clear cell renal cell carcinoma in the absence of functional PBRM1

Project description:ARID2 promotes clear cell renal cell carcinoma in the absence of functional PBRM1

| PRJNA399110 | ENA

Radiomic and transcriptomic analysis for understanding metastatic clear cell renal cell carcinoma

Project description:To understand the relationship of radiomic and transcriptomic features of metastatic clear cell renal cell carcinoma, we performed RNA-sequencing in clear cell renal cell carcinomas (ccRCCs).

2019-09-30 | GSE135091 | GEO

Genomic characterization of Chinese clear cell renal cell carcinoma

Project description:Genomic characterization of Chinese clear cell renal cell carcinoma

| PRJNA523858 | ENA

Side Population Analysis in Clear Cell Renal Cell Carcinoma

Project description:Side Population Analysis in Clear Cell Renal Cell Carcinoma

| PRJNA779732 | ENA

Study of non-clear cell renal cell carcinoma

Project description:Study of non-clear cell renal cell carcinoma

| EGAS00001000926 | EGA

Clear-cell renal cell carcinomas tumors

Project description:Whole genome expression of 39 clear-cell renal cell carcinomas tumors 39 frozen tissue from recent nephrectomies for clear-cell renal cell carcinoma; association with clinical characteristics

2011-05-28 | E-GEOD-29609 | biostudies-arrayexpress

Transcription profiling of human clear cell renal cell carcinoma cell lines

Project description:Systematic somatic mutation screening in human clear cell renal cell carcinoma reveals inactivation of chromatin modification genes

2009-10-01 | E-TABM-770 | biostudies-arrayexpress

Clear cell and chromophobe renal cell carcinoma samples

Project description:Background: Clear cell renal cell carcinoma (ccRCC) and chromophobe renal cell carcinoma (chRCC) can usually be distinguished by histologic characteristics. Occasionally, diagnosis proves challenging and diagnostic difficulty will likely increase as needle biopsies of renal lesions become more common. Method: To identify markers that aid in differentiating ccRCC from chRCC, we used gene expression profiles to identify candidate markers that correlate with histology. 39 antisera and antibodies, including 35 for transcripts identified from gene expression profiling, were evaluated. Promising markers were tested on a tissue microarray (TMA) containing 428 renal neoplasms. Strength of staining of each core on the TMA was formally scored and the distribution of staining across different types of renal neoplasms was analyzed. Results: Based on results from initial immunohistochemical staining of multitissue titer arrays, 23 of the antisera and antibodies were selected for staining of the TMA. For 7 of these markers, strength of staining of each core on the TMA was formally scored. Vimentin (positive in ccRCC) and CD9 (positive in chRCC) best distinguished ccRCC from chRCC. The combination of vimentin negativity and CD9 positivity was found to distinguish chRCC from ccRCC with a sensitivity of 100.0% and a specificity of 95.2%. Conclusions: Based on gene expression analysis, we identify CD9 and vimentin as candidate markers for distinguishing between ccRCC and chRCC. In difficult cases and particularly when the amount of diagnostic tissue is limited, vimentin and CD9 staining could serve as a useful adjunct in the differential diagnosis of ccRCC and chRCC. A disease state experiment design type is where the state of some disease such as infection, pathology, syndrome, etc is studied. Disease State: Stage of Clear Cell renal cell carcinoma (I - V)) disease_state_design

2010-08-20 | E-GEOD-17746 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data